A changing of the guard in stomach cancer?
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
ASCO Plenary – Gilead and Arcus pedal hard with TIGIT
A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.
Interview – Coherus sees the stars aligning at last
After two years Loqtorzi is on the US market at last, and Coherus looks to its Surface acquisition to play the combo game.
ESMO 2023 movers – who won and who lost?
The dust has settled on a momentous ESMO conference, which saw biotech activity amid big pharma’s practice-changing data.
ESMO 2023 – Padcev hits its home run
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.
